Novo Nordisk India and Healthify have partnered to launch an AI-powered obesity care programme, combining GLP-1 therapy with structured lifestyle support. The initiative leverages an AI assistant to guide patients through diet, exercise, and adherence, delivering personalised coaching and real-time insights to help sustain healthy habits.This is more than a therapy programme it’s a data-driven, patient-centric care model.
Why This Partnership Matters
Obesity management requires more than medication it demands continuous support, behavioral guidance, and actionable insights. By integrating AI:
- Patients receive real-time, personalized advice aligned with GLP-1 treatment
- Structured lifestyle interventions are scaled across India, improving access
- Data insights from users inform future global initiatives
The programme represents a next-gen approach where technology enhances treatment outcomes and patient experience.
Leadership Statements
Tushar Vashisht, CEO & Co-Founder, Healthify:
“Our platform ensures patients get structured lifestyle support alongside GLP-1 therapy. With AI-enabled, dietitian-guided care, we aim to make obesity management accessible, personalised, and effective across India.”
Vikrant Shrotriya, MD, Novo Nordisk India:
“As leaders in GLP-1 innovation, we know that combining medication with lifestyle guidance is essential for long-term obesity management. This programme is a significant step in improving patient outcomes and care experience.”
The Novo Nordisk India × Healthify partnership sets a new benchmark in AI-driven healthcare, making obesity care personalised, scalable, and outcome-focused.It underscores a critical insight: AI can bridge the gap between medical innovation and patient adherence, enabling healthier lifestyles at scale.
